Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 12/20 | 0.47 |
| ▸ | IL1B | P01584 | 7/20 | 0.47 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.38 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31021469 | 0.86 | NLRP3 (0.48) | NLRP3IL1BKAT2BKCNH2TNF | |
| SCHEMBL30833903 | 0.86 | KAT2B (0.53) | NLRP3IL1BKAT2BKCNH2 | |
| SCHEMBL25254731 | 0.85 | NLRP3 (0.55) | NLRP3IL1BKCNH2TNF | |
| SCHEMBL25303253 | 0.85 | NLRP3 (0.55) | NLRP3IL1BKCNH2TNF | |
| SCHEMBL30833975 | 0.82 | IL1B (0.55) | NLRP3IL1BKCNH2TNF | |
| SCHEMBL30833884 | 0.82 | IL1B (0.55) | NLRP3IL1BKCNH2TNF | |
| SCHEMBL25303027 | 0.82 | IL1B (0.53) | NLRP3IL1BKAT2B | |
| SCHEMBL25255553 | 0.82 | IL1B (0.53) | NLRP3IL1BKAT2B | |
| SCHEMBL30834003 | 0.79 | IL1B (0.52) | NLRP3IL1BKAT2B | |
| SCHEMBL22655169 | 0.79 | IL1B (0.55) | NLRP3IL1BKAT2BKCNH2TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4613749-A1 | NLRP3 INFLAMMASOME INHIBITOR AND USE THEREOF | TransThera Sciences (Nanjing), Inc. (CN) | 2025-09-10 | — | — | EP | disclosed |
| CN-117986258-A | NLRP3 inflammation corpuscle inhibitor and application thereof | 药捷安康(南京)科技股份有限公司 | 2024-05-07 | — | — | CN | disclosed |